CD33 (i.e. siglec3) is a well-established target in AML and forms the basis of multiple AML therapies, including the immunoconjugate gemtuzumab ozogamicin [3], CAR-T immunotherapy [4], and bispecific antibodies [5]. This evidence concerns the gene CD33 and acute myeloid leukemia.